Peer review reports
From: Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
Original Submission |
20 Jan 2021 |
Submitted |
Original manuscript
|
23 Apr 2021 |
Author responded |
Author comments - Lucheng Zhu
|
Resubmission - Version 2 |
23 Apr 2021 |
Submitted |
Manuscript version 2
|
Publishing |
28 Apr 2021 |
Editorially accepted |
|
7 May 2021 |
Article published |
10.1186/s12885-021-08266-w
|
Learn about peer review